Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Andrew DeRyke

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
International Journal of Antimicrobial Agents|January 16, 2007
Is all free time above the minimum inhibitory concentration the same: implications for beta-lactam in vivo modellingC Andrew DeRyke, David P Nicolau
Expert Opinion on Pharmacotherapy|June 15, 2005
Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patientC Andrew DeRyke, Dana Maglio, David P Nicolau
The Journal of Antimicrobial Chemotherapy|July 22, 2006
Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniaeC Andrew Deryke, Xiaoli Du, David P Nicolau
Pharmacotherapy|February 24, 2007
Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004C Andrew DeRyke, Joseph L Kuti, David P Nicolau
Future Microbiology|January 22, 2024
Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidenceIgnacio Martin-Loeches, Christopher J Bruno, C Andrew DeRyke
Diagnostic Microbiology and Infectious Disease|March 14, 2007
Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessmentC Andrew DeRyke, Joseph L Kuti, David P Nicolau
Antimicrobial Agents and Chemotherapy|July 28, 2010
Colistin dosing and nephrotoxicity in a large community teaching hospitalC Andrew Deryke, Amanda J Crawford, Nizam Uddin, et al.
Drugs|January 10, 2006
Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistanceC Andrew DeRyke, Su Young Lee, Joseph L Kuti, et al.
Chest|September 16, 2005
Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumoniaC Andrew DeRyke, Thomas P Lodise, Michael J Rybak, et al.
Antimicrobial Agents and Chemotherapy|February 7, 2007
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh modelC Andrew DeRyke, Mary Anne Banevicius, Hong Wei Fan, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
International Journal of Antimicrobial Agents|January 16, 2007
Is all free time above the minimum inhibitory concentration the same: implications for beta-lactam in vivo modellingC Andrew DeRyke, David P Nicolau
Expert Opinion on Pharmacotherapy|June 15, 2005
Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patientC Andrew DeRyke, Dana Maglio, David P Nicolau
The Journal of Antimicrobial Chemotherapy|July 22, 2006
Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniaeC Andrew Deryke, Xiaoli Du, David P Nicolau
Pharmacotherapy|February 24, 2007
Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004C Andrew DeRyke, Joseph L Kuti, David P Nicolau
Future Microbiology|January 22, 2024
Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidenceIgnacio Martin-Loeches, Christopher J Bruno, C Andrew DeRyke
Diagnostic Microbiology and Infectious Disease|March 14, 2007
Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessmentC Andrew DeRyke, Joseph L Kuti, David P Nicolau
Antimicrobial Agents and Chemotherapy|July 28, 2010
Colistin dosing and nephrotoxicity in a large community teaching hospitalC Andrew Deryke, Amanda J Crawford, Nizam Uddin, et al.
Drugs|January 10, 2006
Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistanceC Andrew DeRyke, Su Young Lee, Joseph L Kuti, et al.
Chest|September 16, 2005
Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumoniaC Andrew DeRyke, Thomas P Lodise, Michael J Rybak, et al.
Antimicrobial Agents and Chemotherapy|February 7, 2007
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh modelC Andrew DeRyke, Mary Anne Banevicius, Hong Wei Fan, et al.
Pageof 5